Article
PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.
Proceedings of the National Academy of Sciences of the United States of America - 5 Oct 2004
Chen Jing, Deangelo Daniel J, Kutok Jeffery L, Williams Ifor R, Lee Benjamin H, Wadleigh Martha, Duclos Nicole, Cohen Sarah, Adelsperger Jennifer, Okabe Rachel, Coburn Allison, Galinsky Ilene, Huntly Brian, Cohen Pamela S, Meyer Thomas, Fabbro Doriano, Roesel Johannes, Banerji Lolita, Griffin James D, Xiao Sheng, Fletcher Jonathan A, Stone Richard M, Gilliland D Gary
Abstract excerpt
Human stem cell leukemia-lymphoma syndrome usually presents itself as a myeloproliferative disorder (MPD) that evolves to acute myeloid leukemia and/or lymphoma. The syndrome associated with t(8;13)(p11;q12) results in expression of the ZNF198-fibroblast growth factor receptor (FGFR) 1 fusion tyrosine kinase. Current empirically derived cytotoxic chemotherapy is inadequate for treatment of this disease. We...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.